The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies.

Fiche publication

Date publication

septembre 2024

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges , Dr PEIGNAUX Karine

Tous les auteurs :
Kaidar-Person O, Boersma L, De Brouwer P, Weltens C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Peters M, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Valli M, Guckenberger M, Koiter E, Racadot S, Abdah-Bortnyak R, Bartelink H, Struikmans H, Fortpied C, Poortmans PM,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39341505

Résumé

The EORTC 22922/10925 trial aimed to investigate the impact on overall survival (OS) of elective internal mammary and medial supraclavicular (IM-MS) radiation therapy (RT) in breast cancer stage I-III. Surgery for the primary tumour and axillary lymph nodes, chest wall RT, boost RT after whole breast RT in breast conserving therapy (BCT), RT to operated axilla, and systemic therapy were per physician's preference. The aim of the current analysis is to assess breast cancer outcomes according to different locoregional and systemic therapy used in the trial.